PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/679,038	.,			
Filing Date	October 2, 2003				
First Named Inventor	MIKSZTA et al.				
Art Unit	1648				
Examiner Name	TBD				
Attorney Docket Number	P-5331P1P1				

Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevan
Initials* No.1	Number-Kind Code ^{2 (ff known)}	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	
		US-			
		US-			
	ļ	US-			
		US-			
		US-			
	 	US-			
		US-			
		US-			
10100		US-			
	<u> </u>	US-			
		US-			
		US-			
 		US-	 		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ.			
Tricalo		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶			
		EP 1 092 444 A	04-18-2001	Becton, Dickinson and Co.					
	1	WO 02/02179 A	01-10-2002	Becton, Dickinson and Co.					
		WO 02/32454 A	04-25-2002	SmithKline Beecham Bio.					
		WO 02/067983 A	09-06-2002	SmithKline Beecham Bio.					
		WO 02/087494 A	11-07-2002	GlaxoSmithKline Bio.	·				
	<u> </u>	WO 02/083216 A	10-24-2002	Becton, Dickinson and Co.					

Examiner	Date Canaidared	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/679,038			
Filing Date	October 2, 2003			
First Named Inventor	MIKSZTA et al.			
Art Unit	1648			
Examiner Name	TBD			
Attorney Docket Number	P-5331P1P1			

	U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	l	Number-Kind Code ^{2 (f known)}			, iga. 55 / ipp = 1			
		US-						
		US-			,			
		US-						
		US-	,					
		US-						
	<u> </u>	US-						
		US-						
	1	US-						
		US-						
		US-						
	\vdash	US-						
	-	US-						
	 	US-						
	 	US-						
	 	US-						
		US-						
	+	US-						
	+	US-						
	+	US-						

Examiner Initials*	Cite No.1	Foreign Patent Document	IGN PATENT DOCL Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	6
tintalo		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
		WO 02/074336 A	09-26-2002	SmithKline Beecham Bio.		<u> </u>
						_
						<u> </u>
						┢
						<u> </u>
			ļ		<u> </u>	

		The second secon	
		Date	
Funnings	1	Date	
Examiner		Considered	
Signature		Considered	
Siuliature			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/\$B/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Unice; U.S. DEPARTMENT OF COMMERCIA.

U.S. Patent and Trademark Unice; U.S. DEPARTMENT OF COMMERCIA

		uction A	ot of 1995, no persons a	Complete if Known		
Substitu	te for form 1449/PTO			Application Number	10/679,038	
INF	ORMATION	DIS	CLOSURE	Filing Date	October 2, 2003	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	MIKSZTA et al.	
				Art Unit	1648	
	(Use as many she	ets as n	ecessary)	Examiner Name	TBD	
Sheet	3	of	3	Attorney Docket Number	P-5331P1P1	

	T 611	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials*	Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DEGANO P. et al., Intradermal DNA Immunization of Mice Against Influenza A Virus Using the Novel PowderJect System, Vaccine, Vol. 16, No. 4, February 1998 pp. 394-398	
		HAENSLER J. et al., Intradermal DNA Immunization by Using Jet-Injectors in Mice and Monkeys, Vaccine, Vol. 17, No. 7-8, February 1999, pp 628-638	
		RAZ E. et al., Intrad. Gene Immun. the Possible Role of DNA Uptake in the Induction of Cell. Immunity to Viruses, Proc. Nat. Acad. Sci., Vol. 91, No. 20, Sept. 1994 pp 9519-23	
		HELLER R. et al., Intradermal Delivery of Interleukin-12 Plasmid DNA by in Vivo Electroporation, DNA and Cell Biology, Vol. 20, No. 1, January 2001 pp 21-26	
		Supplementary European Search Report for EP 02 76 3212, dated 14 October 2005	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to processing, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.